3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
3
Thoracic
2
Gynecologic
2
Tumor-Agnostic
1
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Myeloid
1
Lymphoid
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Mesothelioma, Malignant
4
Unspecified Adult Solid Tumor, Protocol Specific
3
Lung Neoplasms
3
Wilms Tumor
2
Mesothelioma
2
Kidney Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Non-Small-Cell Lung
2
Unspecified Childhood Solid Tumor, Protocol Specific
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Rhabdoid Tumor
1
Retinoblastoma
1
Pancreatic Neoplasms
1
Optic Nerve Glioma
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neoplasms
1
Myelodysplastic Syndromes
1
Medulloblastoma
1
Liver Neoplasms
1
Leukemia
1
Hepatoblastoma
1
Familial ependymoma
1
Congenital Abnormalities
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
pembrolizumab
4
Cisplatin
3
Carboplatin
3
budigalimab
2
Pemetrexed
2
Paclitaxel
2
Immunotherapy
2
Etoposide
2
Drug Therapy
2
Docetaxel
2
Cyclophosphamide
2
venetoclax
1
trametinib
1
spartalizumab
1
sargramostim
1
rovalpituzumab tesirine
1
ribociclib
1
poly ICLC
1
fludarabine
1
enzalutamide
1
entinostat
1
belinostat
1
UV1 vaccine
1
Tomography, Optical Coherence
1
Thrombopoietin
1
Sunitinib
1
Sirolimus
1
Quality of Life
1
Polymerase Chain Reaction
1
Patient Reported Outcome Measures
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
sargramostim
×
Other solid neoplasm
×
Clear all
NCT04300244
2024-02-29
NIPU
Oslo University Hospital
Phase 2
Active not recruiting
118 enrolled